Tag: ASX: ALA
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
Balancing profit and sustainability in supply chains
Priorities in the supply chain are expanding, moving away from cost as the main driver behind purchasing decisions. Now, sustainability and ethical sourcing are grabbing a portion of the spotlight.
